Dry eye disease is a common condition that affects millions of people worldwide. It occurs when the eyes do not produce enough tears or when the tears evaporate too quickly. This can lead to discomfort, redness, and blurry vision. Many treatment options are available for dry eye disease, including eye drops, medications, and interventional procedures.
In a recent study conducted by Sight Sciences, TearCare, an interventional eyelid procedure, was compared to Restasis eye drops for the treatment of dry eye disease. The results of the study were highly promising and showed significant improvements in tear break up time (TBUT) and Ocular Surface Disease Index (OSDI) with TearCare.
The SAHARA randomized controlled trial involved patients with dry eye disease who were randomly assigned to receive either TearCare or Restasis. Over a six-month period, the patients underwent regular assessments to evaluate their symptoms and measure various endpoints related to dry eye disease.